Loading clinical trials...
Loading clinical trials...
The purpose of this study is to determine whether it is safe to treat lung cancer patients who have undergone an attempt at curative resection with the combination of docetaxel and carboplatin.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Michael Mann
Collaborators
NCT07668037 · Non-Small Cell Carcinoma of Lung, Immunotherapy, and more
NCT02682667 · Multiple Myeloma, Lymphoma, Non-Hodgkin, and more
NCT06529822 · Muscle-Invasive Bladder Carcinoma, Gastroesophageal Adenocarcinoma, and more
NCT07164170 · Non-Small Cell Lung Cancer
NCT06866717 · Non-Small Cell Lung Cancer
Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire
Beijing Chaoyang Hospital
Beijing
Beijing Tumor Hospital
Beijing
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions